Spots Global Cancer Trial Database for An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
Official Title: An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
Study ID: NCT00352261
Conditions
Study Description
Brief Summary: The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Phoenix, Arizona, United States
Research Site, Tucson, Arizona, United States
Research Site, North Chicago, Illinois, United States
Research Site, Rochester, Minnesota, United States
Research Site, Kansas City, Missouri, United States
Research SIte, Springfield, Missouri, United States
Research Site, Butte, Montana, United States
Research Site, Cleveland, Ohio, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Knoxville, Tennessee, United States
Research Site, Dallas, Texas, United States
Research Site, Norfolk, Virginia, United States
Contact Details
Name: Debra Silberg, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
